| Product Name |
Recombinant Human Galectin-3/LGALS3 (LGALS3BP) Protein |
| Product Overview |
This recombinant human Galectin-3/LGALS3 (LGALS3BP) protein includes amino acids 2-250aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization. |
| Target Uniprot Id |
Q08380 |
| Recommended Name |
Galectin-3-binding protein |
| Gene Name |
LGALS3BP |
| Synonyms |
Galectin-3; Gal-3; 35 kDa Lectin; Carbohydrate-Binding Protein 35; CBP 35; Galactose-Specific Lectin |
| Species |
Human |
| Predicted Molecular Mass |
26.0 kDa |
| Expression System |
E.coli |
| Expression Range |
2-250aa |
| Purity |
>95% |
| Formulation |
Lyophilized |
| Buffer |
Phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose |
| Storage Condition |
1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
| Reconstitution Instruction |
Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
| Applications |
Positive Control; Immunogen; SDS-PAGE; WB |
| Research Area |
Cancer |
| Target Function |
Promotes integrin-mediated cell adhesion. May stimulate host defense against viruses and tumor cells. |
| Subcellular Location |
Secreted. Secreted, extracellular space, extracellular matrix. |
| Tissue Specificity |
Ubiquitous. Detected in body fluids such as semen, milk, serum, tears, saliva and urine. Expressed by keratinocytes and fibroblasts. |
